Salud financiera de hoja de balance de Anteris Technologies

Salud financiera controles de criterios 6/6

Anteris Technologies tiene un patrimonio de los accionistas total de A$28.7M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$45.7M y A$17.0M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$30.83m
Patrimonio	AU$28.66m
Total pasivo	AU$17.04m
Activos totales	AU$45.70m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$35.9M) de AVR superan a sus pasivos a corto plazo (A$13.8M).

Pasivo a largo plazo: Los activos a corto plazo de AVR (A$35.9M) superan a sus pasivos a largo plazo (A$3.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: AVR está libre de deudas.

Reducción de la deuda: AVR no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AVR tiene suficiente cash runway para 7 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que AVR disponga de suficiente cash runway para 6 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Anteris Technologies

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera